VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | Latest updates on treating plasma cell dyscrasias

Meral Beksac, MD, Ankara University, Ankara, Turkey, shares the latest updates on the treatment of plasma cell dyscrasias, as presented at EBMT 2021. Dr Beksac outlines the discovery and utilization of novel biomarkers, such as translocation of (11;14), as well as new data from the Phase III ANDROMEDA trial (NCT03201965) investigating daratumumab for the treatment of amyloidosis, bispecific antibody therapies, and the latest updates in chimeric antigen receptor T-cell (CAR-T) therapy. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Disclosures

Dr Meral Beksac, MD, has participated in advisory boards or speakers bureaus with Amgen, BMS, Celgene, Janssen, Oncopeptides, Sanofi and Takeda.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter